Daniel Nomura, Vicinitas Therapeutics. “Deubiquitinase Targeting Chimera (DUBTAC) platform”

Daniel Nomura is a renowned scientist and biotech entrepreneur who has contributed significantly to the field of chemical biology. He is currently a co-founder and scientific advisor at Vicinitas, a biotech focused on developing novel therapies for cancer and inflammatory diseases, as well as a co-founder and board member at Frontier Medicines, a biotech focused on drug discovery.

Nomura began his career as a postdoctoral researcher at the University of California, Berkeley, conducting chemical biology and proteomics research. Later, he joined the faculty at the University of California, Berkeley, where he established a research program centered on the development of new tools and techniques for studying the role of proteins in disease.

In addition to academic research, Nomura has been a successful biotech entrepreneur. In 2015, he co-founded Vicinitas, which has created a unique platform for identifying and targeting protein-protein interactions in cancer and inflammatory diseases. In 2018, he also co-founded Frontier Medicines, which is focused on developing new drugs for difficult disease targets using cutting-edge technologies.

Nomura’s contributions to chemical biology and biotech entrepreneurship have earned him numerous awards and honors, including the National Institutes of Health Director’s Pioneer Award and the Presidential Early Career Award for Scientists and Engineers. His work at Vicinitas and Frontier Medicines is extremely promising in the development of new treatments for some of society’s most difficult diseases.